<DOC>
	<DOC>NCT02248948</DOC>
	<brief_summary>This study aims to evaluate the efficacy of an Omega-3 Fatty Acid Supplement on improving the Attention Deficit Hyperactivity Disorder (ADHD) clinical symptoms.</brief_summary>
	<brief_title>Superiority of Omega-3 Versus Placebo on the Improvement of ADHD in Children</brief_title>
	<detailed_description>This is a multicenter, controlled, randomized, prospective, parallel-group, double-blind study to evaluate the effect of an Omega-3 Fatty Acid Supplement with EPA, DHA, vitamins E and D on ADHD clinical symptoms (according to Diagnostic and Statistical Manual for Mental Disorders, 4th. edition (DSM-IV-TR) criteria) in children between 6 and 11 years. Patients will be randomized to receive either the new omega-3 supplement or a placebo during 6 months.</detailed_description>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Age between 6 and 11 years 11 months. ADHD diagnosis according to DSMIVTR criteria Children whose parents are able to reliably meet all visits and all the tests required for this study based on the researcher judgment Patient representative (either parents or legal guardians) must understand the conditions of the study and sign the informed consent Patients who do not meet diagnostic criteria for ADHD Patients with a previously known allergy or intolerance to the components of Omega 3 supplement Patients with underlying diseases that, according to medical criteria , are not eligible for supplementation with Omega3 fatty acids : fatty liver disease (or other liver disease), bleeding disorders and cardiovascular disease Patients with allergies to fish and /or shellfish Patients who have received ADHD pharmacological treatment or fatty acid supplements at any dose for more than 7 consecutive days within the last 3 months Patients who have received psychological or psychoeducational treatment in the past 3 months Patients who have had some kind of psychometric diagnostic tests in the last year Patients with scores corresponding to a lower mental age (more than 1 year less) according to the Wechsler Intelligence Cubes Scale for Children (WISCIV) Patients with severe emotional problems according to the CAS or STAIC tests Patients participating in another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Omega-3</keyword>
	<keyword>ADHD</keyword>
	<keyword>Quality of Life</keyword>
	<keyword>Inattention</keyword>
	<keyword>Hyperactivity</keyword>
</DOC>